In 2000, the U.S. Patent and Trademark Office released revised interim guidelines that raised the bar for patent eligibility of nucleic acid sequences. ASHG supports the PTO’s new standard of “specific, substantial and credible” utility in its revised guidelines, and suggested an extension of this standard to keep pace with current and planned research.
Related: